Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine

Pharmacoeconomics. 2000 Dec;18(6):609-12. doi: 10.2165/00019053-200018060-00007.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / economics*
  • Carbamates / economics*
  • Carbamates / therapeutic use*
  • Cholinesterase Inhibitors / economics*
  • Cholinesterase Inhibitors / therapeutic use*
  • Cost Savings
  • Humans
  • Neuroprotective Agents / economics*
  • Neuroprotective Agents / therapeutic use*
  • Phenylcarbamates*
  • Rivastigmine

Substances

  • Carbamates
  • Cholinesterase Inhibitors
  • Neuroprotective Agents
  • Phenylcarbamates
  • Rivastigmine